BACKGROUND: The safety and efficacy of short daily hemodialysis has been reported in the USA and Europe, but there is no report on its efficacy in Japanese patients undergoing hemodialysis. METHODS: Twenty-three outpatients (14 men and 9 women, 55.8 +/- 9.6 years old and 11.1 +/- 6.6 years on dialysis) undergoing hemodialysis 3 times/week participated in this study. After 4 weeks' baseline observation under conventional hemodialysis, they were subjected to short daily in-center hemodialysis (DHD, 6 times/week) for 12 weeks and then a 4-week follow-up observation period under conventional hemodialysis. RESULTS: The mean pre-dialysis systolic and diastolic blood pressure significantly decreased in the DHD period. Antihypertensive drugs could be discontinued or the dose was reduced in 6 of 11 patients treated with such drugs. The hematocrit level tended to increase in the DHD period, and recombinant human erythropoietin could be discontinued or reduced in 7 of 14 patients. Localized skin rash caused by the adhesive tape and lidocaine patch at the blood access was observed in only 2 patients, but no other adverse events associated with DHD were noted. CONCLUSION: These results indicate that DHD is safe and more useful than conventional 3 times/week hemodialysis for Japanese patients undergoing hemodialysis. Copyright 2003 S. Karger AG, Basel
BACKGROUND: The safety and efficacy of short daily hemodialysis has been reported in the USA and Europe, but there is no report on its efficacy in Japanese patients undergoing hemodialysis. METHODS: Twenty-three outpatients (14 men and 9 women, 55.8 +/- 9.6 years old and 11.1 +/- 6.6 years on dialysis) undergoing hemodialysis 3 times/week participated in this study. After 4 weeks' baseline observation under conventional hemodialysis, they were subjected to short daily in-center hemodialysis (DHD, 6 times/week) for 12 weeks and then a 4-week follow-up observation period under conventional hemodialysis. RESULTS: The mean pre-dialysis systolic and diastolic blood pressure significantly decreased in the DHD period. Antihypertensive drugs could be discontinued or the dose was reduced in 6 of 11 patients treated with such drugs. The hematocrit level tended to increase in the DHD period, and recombinant humanerythropoietin could be discontinued or reduced in 7 of 14 patients. Localized skin rash caused by the adhesive tape and lidocaine patch at the blood access was observed in only 2 patients, but no other adverse events associated with DHD were noted. CONCLUSION: These results indicate that DHD is safe and more useful than conventional 3 times/week hemodialysis for Japanese patients undergoing hemodialysis. Copyright 2003 S. Karger AG, Basel
Authors: Peter Kotanko; Amit X Garg; Tom Depner; Andreas Pierratos; Christopher T Chan; Nathan W Levin; Tom Greene; Brett Larive; Gerald J Beck; Jennifer Gassman; Alan S Kliger; John B Stokes Journal: Hemodial Int Date: 2015-01-05 Impact factor: 1.812
Authors: Paweena Susantitaphong; Ioannis Koulouridis; Ethan M Balk; Nicolaos E Madias; Bertrand L Jaber Journal: Am J Kidney Dis Date: 2012-02-25 Impact factor: 8.860
Authors: J L Jiang; W Ren; J Song; Q L Sun; X Y Xiao; X Z Diao; Y H Huang; L Lan; P Wang; Z Hu Journal: Braz J Med Biol Res Date: 2013-08-09 Impact factor: 2.590